Drugs.com - New Drug Approvals

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

CHICAGO--(BUSINESS WIRE)--Mar. 17, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

May 13, 2025 - 02:23
 0
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
CHICAGO--(BUSINESS WIRE)--Mar. 17, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...
Read More

Tags:

Previous Article

Ulta Beauty Introduces Mother And Baby Assortment Starring Hatch Mama

Next Article

Pet food maker that's closing Missouri plant adds $450M new plant in Ohio

Related Posts

FDA Grants Interchangeable Designation to Yuflyma (adal...

May 12, 2025  0

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Gi...

May 12, 2025  0

FDA Approves an Updated Label for Tryvio (aprocitentan)...

May 12, 2025  0